By Michael Erman (Reuters) -Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of re.
By Michael Erman (Reuters) -Structure Therapeutics diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results .
Operator: Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call. At this time all lines are in a listen-only mode.